Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TriSalus Life Sciences, Inc. (Nasdaq: TLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. TriSalus identifies itself in these filings as an emerging growth company and an oncology-focused medical technology business built around its Pressure-Enabled Drug Delivery (PEDD) platform and investigational immunotherapy, nelitolimod.
Through Forms 8-K, TriSalus reports material events such as quarterly financial results, business updates, changes in directors, compensation decisions and capital structure actions. Recent 8-K filings describe press releases announcing results for quarters ended June 30 and September 30, 2025, along with revenue performance driven by sales of the TriNav system. Other 8-Ks detail an exchange offer and consent solicitation related to Series A Convertible Preferred Stock, amendments to the certificate of designations, and subsequent conversion of preferred shares into common stock.
These filings also document governance and compensation matters, including director resignations and adjustments to executive base salary and performance-based stock option grants that vest upon achieving specified revenue thresholds. Together, they provide insight into how TriSalus manages its capital structure, aligns management incentives and responds to financing needs while advancing its PEDD-based devices and clinical-stage immunotherapy.
On Stock Titan, SEC documents for TLSI are updated as they are made available through EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, operating results, capital structure changes and governance items, and make it easier to interpret the implications of each report. This allows users to quickly understand what TriSalus is disclosing about its operations, financial condition and strategic decisions without reading every page in detail.
TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 on 27-Jun-2025 for director Arjun J. Desai. On 12-Jun-2025 Desai received a grant of 15,000 non-qualified stock options at an exercise price of $5.50 per share. The options will fully vest on the earlier of (i) 12-Jun-2026 or (ii) the company’s next annual shareholder meeting, subject to continued service. They expire on 11-Jun-2035. After this grant, Desai beneficially owns 65,000 derivative securities; no common shares were acquired or sold, and ownership remains direct. The filing represents routine director compensation and does not disclose any open-market transactions.
Form 4 filing overview: On June 12 2025, TriSalus Life Sciences, Inc. (TLSI) granted Director Gary B. Gordon a non-qualified stock option covering 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on June 11 2035.
Vesting terms: The option will become fully vested on the earlier of (i) the one-year anniversary of the grant date (June 12 2026) or (ii) the date of TLSI’s next annual stockholder meeting, provided Mr. Gordon remains in service through such date.
Post-transaction ownership: Following the grant, Mr. Gordon beneficially owns 56,250 derivative securities (stock options) in TLSI, all held directly. No changes in non-derivative share ownership were reported.
Key takeaways for investors: • This is a routine incentive grant to a board member, aligning director compensation with shareholder interests.
• No open-market purchases or sales were disclosed; therefore, the filing does not signal immediate sentiment regarding TLSI’s current share price.
• The grant size is modest and is unlikely to have a material impact on the company’s capitalization or insider ownership structure.
Form 4 filing overview: On 06/12/2025, TriSalus Life Sciences, Inc. (TLSI) director Kerry R. Hicks was granted a non-qualified stock option for 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on 06/11/2035 and will vest in full on the earlier of 06/12/2026 or the company’s next annual shareholder meeting, subject to continued board service.
Following the grant, Mr. Hicks now beneficially owns 89,222 derivative securities (principally stock options). The filing indicates direct ownership; no indirect holdings were reported. No purchases or sales of common stock occurred, and the filing does not disclose any change to Mr. Hicks’ non-derivative share count.
The transaction was coded “A” (acquisition), routine for director compensation, and was not executed under a Rule 10b5-1 plan. Because the filing relates only to an option grant—without an accompanying open-market trade—its immediate market impact is typically limited. Nevertheless, investors may view the award as modest alignment of director incentives with shareholder interests through long-dated equity compensation.